Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water”In the company’s words, NCT07941557 on ClinicalTrials.gov
- Tested for
- Cardiac Fibrosis
- Main trialPhase 1
- “This is the first study of ABS-169 in people. ABS-169 is an oral investigational medicine that blocks MD2-TLR4 signalling, a pathway involved in inflammation and scarring (fibrosis) of organs such as the heart. The study will test single doses of ABS-169 or placebo in healthy adult volunteers to find out how safe and well tolerated it is, how much of the medicine gets into the blood and how quickly it is removed, and whether taking it with a high-fat meal changes how it is absorbed. Up to 40 healthy adults aged 18 to 55 will take part at one study centre in Melbourne, Australia.”In the company’s words, NCT07941557 on ClinicalTrials.gov
Coming up1
- 1 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07941557
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 1 Aug 2027 | First-in-Human Study of ABS-169 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026